Long‐term health‐related quality of life in head and neck cancer survivors: A large multinational study
Katherine J. Taylor,Cecilie D. Amdal,Kristin Bjordal,Guro L. Astrup,Bente B. Herlofson,Fréderic Duprez,Ricardo R. Gama,Alexandre Jacinto,Eva Hammerlid,Melissa Scricciolo,Femke Jansen,Irma M. Verdonck‐de Leeuw,Giuseppe Fanetti,Orlando Guntinas‐Lichius,Johanna Inhestern,Tatiana Dragan,Alexander Fabian,Andreas Boehm,Ulrike Wöhner,Naomi Kiyota,Maximilian Krüger,Pierluigi Bonomo,Monica Pinto,Sandra Nuyts,Joaquim Castro Silva,Carmen Stromberger,Pol Specenier,Francesco Tramacere,Ayman Bushnak,Pietro Perotti,Michaela Plath,Alberto Paderno,Noa Stempler,Maria Kouri,Vincent Grégoire,Susanne Singer,on behalf of the EORTC Quality of Life Group and the EORTC Head and Neck Group
DOI: https://doi.org/10.1002/ijc.34861
2024-02-07
International Journal of Cancer
Abstract:What's new? Head and neck cancer and its treatments can cause side reffects that negatively affect health‐related quality of life (HRQoL). Little is known about the long term HRQoL of survivors of head and neck cancer beyond 1 year. Here, the authors examined the association between treatment and HRQoL at least 5 years after diagnosis. For symptoms concerning dry mouth, sticky saliva, problems swallowing, mouth pain, problems opening the mouth, problems with senses, and fatigue, they found that patients who had undergone a single mode of treatment had better outcomes than those who had had multimodal treatment. Head and neck cancer (HNC) patients suffer from a range of health‐related quality of life (HRQoL) issues, but little is known about their long‐term HRQoL. This study explored associations between treatment group and HRQoL at least 5 years' post‐diagnosis in HNC survivors. In an international cross‐sectional study, HNC survivors completed the European Organization for Research and Treatment of Cancer (EORTC) quality of life core questionnaire (EORTC‐QLQ‐C30) and its HNC module (EORTC‐QLQ‐H&N35). Meaningful HRQoL differences were examined between five treatment groups: (a) surgery, (b) radiotherapy, (c) chemo‐radiotherapy, (d) radiotherapy ± chemotherapy and neck dissection and (e) any other surgery (meaning any tumour surgery that is not a neck dissection) and radiotherapy ± chemotherapy. Twenty‐six sites in 11 countries enrolled 1105 survivors. They had a median time since diagnosis of 8 years, a mean age of 66 years and 71% were male. After adjusting for age, sex, tumour site and UICC stage, there was evidence for meaningful differences (10 points or more) in HRQoL between treatment groups in seven domains (Fatigue, Mouth Pain, Swallowing, Senses, Opening Mouth, Dry Mouth and Sticky Saliva). Survivors who had single‐modality treatment had better or equal HRQoL in every domain compared to survivors with multimodal treatment, with the largest differences for Dry Mouth and Sticky Saliva. For Global Quality of Life, Physical and Social Functioning, Constipation, Dyspnoea and Financial Difficulties, at least some treatment groups had better outcomes compared to a general population. Our data suggest that multimodal treatment is associated with worse HRQoL in the long‐term compared to single modality.
oncology